New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 17, 2014
08:32 EDTABIO, LHARCA Biopharma announces screening of first patient in Phase 2B/3 trial
ARCA biopharma announced that the first patient has been genetically screened in GENETIC-AF, its Phase 2B/3 adaptive design clinical trial. The GENETIC-AF trial will evaluate Gencaro as a potential treatment for the prevention of atrial fibrillation in patients with heart failure and/or left ventricular dysfunction who also have a specific genotype of the beta-1 adrenergic receptor, which is believed to be present in approximately 50% of the U.S. population. There are currently seven active clinical trial sites recruiting patients for GENETIC-AF. The company anticipates having approximately 50 clinical trial sites for the Phase 2B portion of the trial. Last week, ARCA hosted the initial GENETIC-AF Investigator Meeting which brought together the physicians and research coordinators participating in the trial for information sharing and study-specific training.
News For ABIO;LH From The Last 14 Days
Check below for free stories on ABIO;LH the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 29, 2014
06:45 EDTLHLabCorp removed from short-term buy list at Deutsche Bank
Subscribe for More Information
September 26, 2014
10:09 EDTLHHigh option volume stocks
Subscribe for More Information
September 25, 2014
09:13 EDTLHOn The Fly: Pre-market Movers
HIGHER: LipoScience (LPDX), up 63% after agreeing to be acquired by LabCorp (LH) for $5.25 per share in cash... Magnum Hunter (MHR), up 12.5% after announcing that throughput volumes on Eureka Hunter's gas gathering pipeline system have increased to about 316,500 MMBtu per day... Jabil Circuit (JBL), up 4.7% following its report of better than expected fourth EPS and revenue... JD.com (JD), up 0.7% after the stock was initiated with an Outperform rating at Macquarie. LOWER: Yahoo (YHOO), down 0.6% after RBC Capital downgraded its rating on the stock to Sector Perform from Outperform, saying the risk/reward is less attractive following Alibaba's (BABA) initial public offering... HB Fuller (FUL), down 15% after reporting quarterly results and guidance that missed analyst estimates... Omnova Solutions (OMN), down 10.8% after its Q3 adjusted EPS missed expectations... Pacira Pharmaceuticals (PCRX), down 9.2% after receiving an FDA warning letter over certain promotional materials on Exparel.
07:02 EDTLHLabCorp acquires LipoScience
LabCorp (LH) and LipoScience (LPDX) announced that they entered into a definitive merger agreement under which LabCorp would acquire LipoScience for a purchase price of $5.25 per share in cash, or a transaction value of $85.3M which represents a total enterprise value of approximately $63M. The Board of Directors of LipoScience has unanimously approved the agreement and recommended approval of the transaction by LipoScience’s stockholders. The transaction is subject to customary closing conditions including the expiration or early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and approval by LipoScience’s stockholders. The transaction is expected to close in Q4.
07:00 EDTLHLabCorp acquires LipoScience for $5.25 per share in cash
06:58 EDTLHLabCorp agrees to acquire LipoScience for $5.25 per share
Subscribe for More Information
06:56 EDTLHLabCorp to acquire LipoScience for $5.25 per share in all cash transaction
06:56 EDTLHLabCorp agrees to acquire LipoScience for $5.25 per share
Subscribe for More Information
September 16, 2014
08:04 EDTLH, ABIOLabCorp, ARCA Biopharma present GENETIC-AF poster at HFSoA meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use